Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of reduced-dose Cervarix HPV vaccination schedules
NL-OMON53042Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (4 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoints: HPV16 and HPV18 type-specific antibody levels after two-dose schedule, Long-term kinetics of HPV16 and HPV18 antibody levels after two-dose schedule and 4 more. Started Aug 2014; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON53042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53042.